Development of a technology-based behavioral vaccine to prevent adolescent depression: A health system integration model

Efforts to prevent depression have become a key health system priority. Currently, there is a high prevalence of depression among adolescents, and treatment has become costly due to the recurrence patterns of the illness, impairment among patients, and the complex factors needed for a treatment to be effective. Primary care may be the optimal location to identify those at risk by offering an Internet-based preventive intervention to reduce costs and improve outcomes. Few practical interventions have been developed. The models for Internet intervention development that have been put forward focus primarily on the Internet component rather than how the program fits within a broader context. This paper describes the conceptualization for developing technology based preventive models for primary care by integrating the components within a behavioral vaccine framework. CATCH-IT (Competent Adulthood Transition with Cognitive-behavioral, Humanistic and Interpersonal Training) has been developed and successfully implemented within various health systems over a period of 14 years among adolescents and young adults aged 13–24.☆☆Disclosures: Benjamin W. Van Voorhees has served as a consultant to Prevail Health Solutions, Inc., Mevident Inc., San Francisco and Social Kinetics, Palo Alto, CA, and the Hong Kong University to develop Internet-based interventions. In order to facilitate dissemination, the University of Chicago agreed to grant a no-cost license to Mevident Incorporated (3/5/2010) to develop a school-based version. Neither Dr. Van Voorhees nor the university will receive any royalties or equity. Dr. Van Voorhees agreed to assist the company in adapting the intervention at the rate of $1000/day for 5.5 days. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).*Corresponding author at: Department of Pediatrics, University of Illinois at Chicago, Children\u27s Hospital, University of Illinois Hospital & Health Sciences System, 840 South Wood Street (MC 856), Chicago, IL 60612-7324. HHS Public Access Author manuscript Internet Interv. Author manuscript; available in PMC 2018 November 21. Published in final edited form as: Internet Interv. 2015 September ; 2(3): 303–313. doi:10.1016/j.invent.2015.07.004. Autho

Immunoproteomic identification of anti-C9 autoimmune antibody in patients with seronegative obstetric antiphospholipid syndrome

<div><p>Immunoproteomic analysis was performed to identify unknown, pathology-related molecules in patients with seronegative (SN) obstetric antiphospholipid syndrome (APS) who clinically satisfied the diagnostic criteria for APS, but not the serological criteria. We collected peripheral blood from 13 SN-APS outpatients with known thrombotic predisposition, 13 with no known thrombotic predisposition, and four multiparous women with no history of miscarriage (control). Plasma proteins from volunteers were purified and used as plasma protein antigens. Two-dimensional immunoblotting was performed using pooled control or SN-APS serum samples as the primary antibodies. Mass spectrometry of reactive spots specific to SN-APS serum led to the identification of complement molecule C9. Western blotting using commercial purified alkylated C9 was performed to detect autoantibodies. Examination of individual patient serum identified reactivity in one patient with, and in two patients without known thrombotic predisposition. This study suggests that SN-APS pathologies were associated with autoantibodies that react to specific C9 epitopes.</p></div

Predicting Future Risk of Depressive Episode in Adolescents: The Chicago Adolescent Depression Risk Assessment (CADRA)

PURPOSE A risk prediction index, similar to those used for other disorders, such as cardiovascular disease, would facilitate depression prevention by identifying those who would benefit most from preventative measures in primary care settings

Anti-C9 antibody detection by western blotting using commercially available purified C9.

<p>Purified C9 (100 ng), with or without alkylation by iodoacetamide (IAM), was subjected to SDS-PAGE. (A) Alkylated C9 showed sharper band of higher molecular weight. (B) The band corresponding to purified alkylated C9 was clearly detected by pooled serum from SN-APS patients.</p

The effect of urea-mediated denaturation on immunoreactivity to alkylated C9.

<p>Purified alkylated C9 (100 ng), dissolved with or without 8M urea prior to IAM treatment, were subjected to SDS-PAGE (A). Serum sample no. 15 reacts with alkylated C9 regardless of urea denaturation (B).</p

Analysis of the anti-C9 antibody in individual serum samples from SN-APS patients.

<p>Purified alkylated C9 (50 ng) was subjected to SDS-PAGE thrice, and blotted onto PVDF membranes (membrane 1, 2, and 3). Each membrane was cut into strips corresponding to the electrophoresed lanes and reacted with individual patient serum samples. As a positive control, serum no. 15 was included on a strip from each membrane. In the figure, the cut strips that were subjected to western blotting are arranged and shown in the order of loading on the original membrane. The lines separating the lanes were not generated by image processing, but are artifacts of the experimental procedure used to separate parts of the membrane for reaction with different serums. Anti-C9 antibody was detected in two of 13 SN-APS patients without known thrombophilia, one of 13 SN-APS patients with thrombophilia, and none of the four control samples.</p

Sample characteristics and experimental results.

<p>Sample characteristics and experimental results.</p

Separation of plasma proteins by 2-DE.

<p>Blood from six female volunteers was purified to provide plasma protein antigens, which were subjected to 2-DE and stained with silver nitrate.</p